Abstract:Background Most of the structural modifications to evodiamine (EVO) have focused on the 3- and 10-positions, while structural modifications to the EVO 2-position have not yet been reported. In this study, we investigated the scaffold diversity and bioactivity of EVO from position 2 to gain more insight into the influence of the chemical space around EVO on bioactivity. Objective The study aims to synthesize two derivatives of EVO with hydroxy groups, 8a and 8b, and to investigate the antitumor activity of EVO derivatives with hydroxy groups compared to EVO. Methods The synthesized compounds were structurally characterized by H-1 NMR, C-13 NMR, and mass spectrometry. The effects of compounds 8a, 8b, and EVO on the proliferation of H460, A549, and Eca109 cells in vitro were determined by MTT. The effect of EVO, 8a and 8b on apoptosis of H460 cells was investigated by the annexed V-FITC/propidium iodide (PI) combination assay. The expression of EVO, 8a and 8b on apoptosis-related proteins was examined by Western blot analysis. To simulate the binding ability between small molecules and proteins, molecular docking calculations of EGFR(WT) and EGFR(T790M) with 8a and 8b, respectively, were performed using Schrodinger software. Results In the cytotoxicity assay, compound 8b showed lower IC50 values for the three tumor cell lines (6.69 & mu;M for H460 cells, 20.02 & mu;M for A549 cells, and 16.47 & mu;M for Eca109 cells) compared to compound 8a and EVO, and 8b induced apoptosis by affecting apoptosis-related proteins CRAF, AKT, and ERK in a late apoptotic manner. The molecular docking results showed that 8b has a good binding ability to EGFR upstream of apoptosis-related proteins. Conclusion These findings suggest that 8b has significantly higher antitumor biological activity than EVO and 8a. This antitumor effect has important implications for the study of EVO derivatives in antitumor models.

Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa

Research progress on evodiamine, a bioactive alkaloid of Evodiae fructus: Focus on its anti-cancer activity and bioavailability (Review)

Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia Rutaecarpa

Advances in the Research of Biological Activities of Evodiamine Derivatives

Pharmacological Actions of Multi-Target-Directed Evodiamine

New Tricks for an Old Natural Product: Discovery of Highly Potent Evodiamine Derivatives As Novel Antitumor Agents by Systemic Structure-Activity Relationship Analysis and Biological Evaluations.

Evodiamine, A Novel Inhibitor Of The Wnt Pathway, Inhibits The Self-Renewal Of Gastric Cancer Stem Cells

Major Indole Alkaloids in Evodia Rutaecarpa: The Latest Insights and Review of Their Impact on Gastrointestinal Diseases

Therapeutic Effects of the major alkaloid constituents of Evodia rutaecarpa in Alzheimer's disease

Antiproliferative Effects of Alkaloid Evodiamine and Its Derivatives

Studied on the antitumor activities of alkaloid from Evodia rutaecarpa

Recent advances in the antitumor effects of evodiamine

The Design, Synthesis, and Evaluation of Evodiamine Derivatives with Hydroxy Groups

Maintaining calcium homeostasis as a strategy to alleviate nephrotoxicity caused by evodiamine

Antianoxic action of evodiamine, an alkaloid in Evodia rutaecarpa fruit

Pharmacological Basis for the Use of Evodiamine in Alzheimer’s Disease: Antioxidation and Antiapoptosis

Rutaecarpine: A promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu)

Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer

Studies on the Chemical Constituents of Evodia Rutaecarpa and Evodia Rutaecarpa Passed with Liquorice and Biological Activities

Design, Synthesis and Bioactivity Evaluation of Novel N-phenyl-substituted Evodiamine Derivatives As Potent Anti-Tumor Agents

The pharmacokinetics profiles, pharmacological properties, and toxicological risks of dehydroevodiamine: A review